Episode 443 - Peter Leary, MD
I'm Aware That I'm Rare: the phaware® podcast
Release Date: 11/20/2023
I'm Aware That I'm Rare: the phaware® podcast
Dr. Richard Channick, dives into the evolving world within pulmonary hypertension -- interstitial lung disease (PH-ILD). He sheds light on why early diagnosis matters and how new therapies are transforming care. Learn about the latest FDA-approved treatment and what’s on the horizon. This Special Edition episode is sponsored by and . Hello, I'm Rich Channick. I'm Professor of medicine at UCLA Medical Center and Co-Director of the Pulmonary Vascular Disease Program at UCLA. I've been there for the last six-and-a-half years, but have been involved with pulmonary hypertension for over 30...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Richard Channick, dives into the evolving world within pulmonary hypertension -- interstitial lung disease (PH-ILD). He sheds light on why early diagnosis matters and how new therapies are transforming care. Learn about the latest FDA-approved treatment and what’s on the horizon. This Special Edition episode is sponsored by and . Learn more about pulmonary hypertension trials at . Engage for a cure: #phaware Share your story: Like, Subscribe and Follow us: . #phawareMD #PHILD #PHOCUSstudy #PROSERAStudy
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Ioana Preston explores the emerging field of pulmonary hypertension associated with interstitial lung disease (PH-ILD). She discusses the growing recognition of PH-ILD, especially after the introduction of inhaled treprostinil as a treatment, and highlights the importance of early screening and diagnosis. Dr. Preston also delves into the challenges of treating rare diseases, the evolution of research, and the hope for future therapies that could significantly improve patients' lives. This insightful conversation sheds light on a critical yet often overlooked aspect of pulmonary care,...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Ioana Preston explores the emerging field of pulmonary hypertension associated with interstitial lung disease (PH-ILD). She discusses the growing recognition of PH-ILD, especially after the introduction of inhaled treprostinil as a treatment, and highlights the importance of early screening and diagnosis. Dr. Preston also delves into the challenges of treating rare diseases, the evolution of research, and the hope for future therapies that could significantly improve patients' lives. This insightful conversation sheds light on a critical yet often overlooked aspect of pulmonary care,...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Raj Parikh from Hartford Hospital discusses the development of the PH-ILD Detection tool, a screening tool designed to help detect pulmonary hypertension (PH) in patients with interstitial lung disease (ILD) at an early stage. Early detection is critical, as there is often a significant delay in diagnosis of PH in ILD patients, leading to worsened outcomes. This Special Edition episode is sponsored by . My name is Raj Parikh. I'm the Director of the Pulmonary Hypertension Center at Hartford Hospital in Hartford, Connecticut. I did a lot of my training kind of all over. I went to medical...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Raj Parikh from Hartford Hospital discusses the development of the PH-ILD Detection tool, a screening tool designed to help detect pulmonary hypertension (PH) in patients with interstitial lung disease (ILD) at an early stage. Early detection is critical, as there is often a significant delay in diagnosis of PH in ILD patients, leading to worsened outcomes. This Special Edition episode is sponsored by . Learn more about pulmonary hypertension trials at . Engage for a cure: #phaware Share your story: Like, Subscribe and Follow us: . #phawareMD #PHILD
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Ron Zolty delves into groundbreaking advancements in treating pulmonary arterial hypertension. From the historical use of vasodilators to the revolutionary promise of sotatercept and seralutinib, Dr. Zolty unpacks how science is moving closer to halting—and possibly even reversing—PAH. This Special Edition episode is sponsored by . My name is Ron Zolty. I'm a cardiologist working in advanced heart failure and heart transplantation. In my training, I had to do a lot of catheterizations in patients with pulmonary arterial hypertension. I trained at the University of Colorado in...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Ron Zolty delves into groundbreaking advancements in treating pulmonary arterial hypertension. From the historical use of vasodilators to the revolutionary promise of sotatercept and seralutinib, Dr. Zolty unpacks how science is moving closer to halting—and possibly even reversing—PAH. This Special Edition episode is sponsored by . Learn more about pulmonary hypertension trials at . Engage for a cure: #phaware Share your story: Like, Subscribe and Follow us: . #phawareMD #clinicaltrial #PROSERA
info_outlineI'm Aware That I'm Rare: the phaware® podcast
For decades, researchers have sought better treatments for pulmonary hypertension in interstitial lung disease, a condition that drastically impacts patients’ quality of life. In this episode, Dr. Rajan Saggar dives into the latest advancements, including new inhaled medications, upcoming clinical trials, and the push for more personalized treatment approaches. This Special Edition episode is sponsored by and . I am Dr. Rajan Saggar. I'm Co-Director of the Pulmonary Hypertension Program at UCLA, and my Co-Director is Dr. Richard Channick. We work at that program together. One of my...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
For decades, researchers have sought better treatments for pulmonary hypertension in interstitial lung disease, a condition that drastically impacts patients’ quality of life. In this episode, Dr. Rajan Saggar dives into the latest advancements, including new inhaled medications, upcoming clinical trials, and the push for more personalized treatment approaches. This Special Edition episode is sponsored by and Learn more about pulmonary hypertension trials at . Engage for a cure: #phaware Share your story: Like, Subscribe and Follow us: . #phawareMD...
info_outlineIn this episode, Peter Leary, MD talks about factors that might lead to over-treatment, under-treatment, or "just-right" treatment and emphasizes that guidelines are important but there is no "one-size fits all" approach to treatment of pulmonary hypertension.
Peter Leary is the director of the pulmonary vascular disease program at the University of Washington. He also has a PhD in epidemiology and is very interested in clinical and translational research for patients with pulmonary hypertension locally, nationally, and internationally.
Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware
Share your story: [email protected] #phawareMD @uwepidemiology